This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
To optimize outcomes for patients who begin dopamine agonist therapy, routine follow-up of prolactin is imperative for guiding dose adjustment.1
Serum prolactin should be measured 1 month after initiating dopamine agonist therapy and routinely repeated, as necessary.1,2
Example
Example
Example
Aside from monitoring prolactin levels and adjusting dopamine agonist therapy to achieve prolactin normalisation, other follow-up assessments should be conducted during treatment.1
Example
Example
Example
Example
Dopamine agonists should be given continuously for at least 2 years. After this time, therapy can be tapered and perhaps even discontinued if prolactin levels have remained at normal levels for 2 years and there is no visible tumor remaining on MRI.1
If treatment tapering/discontinuation is pursued, careful follow-up is required to monitor for recurrence.1
Example
Dostinex (cabergoline) prescribing information can be found here
References
See general information including pathophysiology and etiology
Understand what signs to look for and explore two patient case studies
Recognise which tests to order and what the results indicate
Determine therapy based on clinical and patient factors
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021